Clark Estates Inc. NY Sells 650,000 Shares of Haleon plc (NYSE:HLN)

Clark Estates Inc. NY cut its position in shares of Haleon plc (NYSE:HLN) by 24.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,000,000 shares of the company’s stock after selling 650,000 shares during the quarter. Haleon accounts for 3.9% of Clark Estates Inc. NY’s portfolio, making the stock its 6th largest position. Clark Estates Inc. NY’s holdings in Haleon were worth $21,160,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in HLN. Manning & Napier Advisors LLC acquired a new stake in Haleon during the 2nd quarter valued at $2,833,000. Chartwell Investment Partners LLC raised its position in Haleon by 107.8% during the third quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company’s stock valued at $5,030,000 after buying an additional 246,594 shares during the period. Cetera Advisors LLC lifted its stake in Haleon by 524.3% in the 1st quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock worth $696,000 after acquiring an additional 68,857 shares in the last quarter. Cetera Investment Advisers lifted its position in shares of Haleon by 106.3% in the first quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock worth $1,985,000 after purchasing an additional 120,447 shares in the last quarter. Finally, Crossmark Global Holdings Inc. grew its position in Haleon by 55.6% during the third quarter. Crossmark Global Holdings Inc. now owns 480,760 shares of the company’s stock valued at $5,087,000 after purchasing an additional 171,877 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Up 0.1 %

Shares of Haleon stock opened at $9.59 on Wednesday. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock has a 50 day moving average price of $9.99 and a two-hundred day moving average price of $9.40. The stock has a market capitalization of $43.41 billion, a P/E ratio of 28.21, a PEG ratio of 2.89 and a beta of 0.30.

Wall Street Analyst Weigh In

HLN has been the subject of several recent research reports. Berenberg Bank started coverage on Haleon in a report on Tuesday, August 6th. They set a “buy” rating for the company. UBS Group raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley raised their price target on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a report on Friday, September 20th. Finally, The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.